IP Journal of Otorhinolaryngology and Allied Science

Print ISSN: 2582-4147

Online ISSN: 2582-421X

CODEN : IJOABK

IP Journal of Otorhinolaryngology and Allied Science (JOAS) open access, peer-reviewed quarterly journal publishing since 2018 and is published under the Khyati Education and Research Foundation (KERF), is registered as a non-profit society (under the society registration act, 1860), Government of India with the vision of various accredited vocational courses in healthcare, education, paramedical, yoga, publication, teaching and research activity, with the aim of faster and better dissemination of knowledge, we will be publishing the article more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 483

PDF Downloaded: 309


Get Permission Paliwal and Vaidya: A case report on use of ivermectin as nasal drop in a case of nasal myiasis


Background

Myiasis presents commonly in tropical regions, characterized by tissue infestation by fly larvae, known as maggots. Flies typically deposit their eggs in open wounds or near inflamed skin, often caused by moisture. These eggs hatch within 8 to 24 hours, with the larvae penetrating damaged skin, creating deep lesions prone to bacterial infection. Without treatment, these chronic wounds progress, leading to septicaemia and potentially death.

Conventional treatment involves manual removal of larvae, wound cleaning, surgical removal of dead tissue, and dressing application. Larvae removal is challenging and painful, often necessitating the use of topical parasiticides like ivermectin. Ivermectin, applied topically, selectively binds to chloride ion channels, increasing cell permeability and causing nerve or muscle cell hyperpolarization, ultimately leading to parasite death.

Case Report

A 52 year old male came in ENT OPD with the complain of nasal bleeding and recurrent sneezing since 1 day. He was a known case of right sided hemiparesis, with history of covid infection complicated with rhinocerebral mucormycosis- operated in 2022. He had history of diabetes mellitus during covid infection for which he was on medication in 2022, then stopped medication as his sugar levels came to normal. On General Examination he was average built, well oriented, Cooperative B Pmmhg Pulse74/ minutesnormovolumic with regular rhythm, afebrile, all point of examination like piccwere absentdetected.Local Examination of nose was done. There was side. Crusting was found on mucous membrane, and septum was found deviated towards right with mid septal tear in right nasal cavity. Live Maggots were found in septal tear, ethmoid and maxillary sinus opening. On Post Rhinoscopy examination there was no Post Nasal Tricklinginvestigations which are necessary in the preop period. The patient was then planned for debridement and suction clearance of maggots.

Investigations

  1. ENT profile- CBC, Urine R/M, Blood sugar, RFT, LFT was done.

  2. CT PNS was suggestive of nasal mucosa atrophy with multiple maggots present extending to ethmoid sinus, maxillary sinus, frontal sinus and base of skull.

  3. Direct nasal endoscopy shown multiple live maggots moving out of sinuses and in nasal cavity.

Figure 1
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/54ca36f8-d726-438b-8936-a3144f21d275image1.png
Figure 2
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/54ca36f8-d726-438b-8936-a3144f21d275image2.png

Management

Patient was started with injectable antibiotics, ceftriaxone 1gm I/V BD and the patient was also given oral antiparasitic medication i.e. 12 mg tab ivermectin daily for 3 days. Normal Saline drops mixed with crushed 2 tabs of ivermectin 12mg were also instilled in patient with frequency of 2 drops QID. Multiple sitting of Nasal endoscopy suction and clearance was done under LA with sedation and under local anesthesia. Multiple washes were given and Dead Maggots were removed from ethmoid sinus, maxillary sinus, sphenoid sinus and base of skull and septum followed by continued nasal washing with ivermectin saline solution.

Discussion

Myiasis is a condition in humans caused by the infestation of fly larvae belonging to the Diptera order.1, 2 Fly larvae from various families including Muscoidea (such as Musca domestica, the common house fly), Oestridae (for instance, Oestrus ovis, the Sheep Nasal fly), Calliphoridae (like Cochliomyia hominivorax, the New World Screwworm fly), and Sarcophagidae (such as Wohlfahrtia magnifica, the Spotted flesh fly) are commonly associated with myiasis.3 These larvae can be categorized as obligatory, facultative, or accidental parasites. In obligatory myiasis, maggots develop in and feed on non-necrotic tissue of living hosts, while facultative myiasis involves maggots feeding on necrotic tissues or decaying materials but not necessarily requiring a living host. Accidental myiasis occurs when larvae are inadvertently ingested or deposited in tissues, becoming accidental parasites.

Myiasis can also be classified based on the affected area. Nasal myiasis, unlike most forms, can lead to potentially fatal outcomes, often involving destruction of nasal soft tissue and bone. Complications such as pneumocephalus, secondary meningitis, and bacterial sepsis have been documented.4, 5, 6, 7, 8 Risk factors identified in an Indian study include atrophic rhinitis, leprosy, poor nutritional status, and low socioeconomic status.4 Similar to leprosy, mucocutaneous leishmaniasis ulcerations may predispose individuals to nasal myiasis, especially in those with low socioeconomic status and living in rural areas.

Although rare, cases of nasal myiasis have been reported in resource-rich countries, including among previously healthy travellers.9, 10, 11 Additionally, locally acquired cases have been observed in immunocompromised individuals, 12, 13, 14 and nosocomial nasal myiasis outbreaks have been documented in intensive care units in intubated and semi-conscious patients in USA,15, 16, 17, 18 Korea,19 and Taiwan.20

Successful treatment involves complete removal of larvae to prevent secondary infections.3 While extreme surgical interventions are avoided, topical agents like turpentine, mineral oil and chloroform and manual extraction remain common treatment modalities.3, 7, 21 Endoscopic removal has emerged as the preferred treatment,12, 22, 23 although multiple procedures may be necessary due to the high number of larvae sometimes present.24

Ivermectin, a semi-synthetic derivative of avermectin, has gained attention for its efficacy against various parasites, including those causing myiasis. It acts by disrupting neurotransmission through ligand-gated chloride channels in invertebrates, leading to paralysis and death.25 Ivermectin's low affinity for mammalian central nervous system and inability to penetrate the blood-brain barrier make it safe for use. Recent research suggests additional immunomodulatory effects, further expanding its potential applications.26, 27 Successful use of oral ivermectin alongside manual extraction has been reported in treating nasal and rhino-orbital myiasis cases.7, 9, 28, 29, 30 Dosages typically range from 2 mg to 0.2 mg/kg, with repeated courses possibly necessary.9 Ivermectin is readily available in many resource-poor countries, often in liquid formulations.

Conclusion

With this, the conclusion drawn from the case study was that the most effective tool found in the complete clearance of maggots was the solution made by combining crushed ivermectin tablet and saline. The vigorous routinely done nasal irrigation with this solution benefited the patient to a larger extent and resulted in complete clearance in approximately three to four settings. Thus the antiparasitic oral tablet IVERMECTIN can be used in a nasal drop formulation for the aid of nasal myiasis. It is important to note that the liquid formulation of ivermectin, which was used in our case, has twice the bioavailability of oral tablet.

Source of Funding

None.

Conflict of Interest

None.

References

1 

SY Tay BR Ramasamy DA Watson M Montoya Treatment of nasal myiasis with ivermectin irrigationBMJ Case Rep2018bcr201722414210.1136/bcr-2017-224142

2 

K Mumcuoglu Other Ectoparasites: Leeches, Myiasis and Sand Fleas Manson’s Trop Dis20148437

3 

F Francesconi O Lupi MyiasisClin Microbiol Rev201225179105

4 

H Sharma D Dayal SP Agrawal Nasal myiasis: review of 10 years experienceJ Laryngol Otol1989103548991

5 

F J Uriarte S R Ell Doctor, there are maggots in my noseJ R Soc Med199790116345

6 

G Kuruvilla RR Albert A Job VT Ranjith P Selvakumar Pneumocephalus: a rare complication of nasal myiasisAm J Otolaryngol20062721335

7 

S Thomas P Nair K Hegde Nasal myiasis with orbital and palatal complicationsBMJ Case Rep20104710.1136/bcr.08.2010.3219

8 

SF Mircheraghi SF Mircheraghi HRA Riabi A Parsapour Nasal nosocomial myiasis infection caused by chrysomya bezziana (diptera: calliphoridae) following the septicemia: a case reportIran J Parasitol20161122849

9 

I Smillie PK Gubbi HC Cocks Nasal and ophthalmomyiasis: case reportJ Laryngol Otol201012489345

10 

H Einer E Ellegård Nasal myiasis by Oestrus ovis second stage larva in an immunocompetent man: case report and literature reviewJ Laryngol Otol201112577456

11 

L Delhaes B Bourel F Pinatel JC Cailliez D Gosset D Camus Human nasal myiasis due to Oestrus ovisParasite20018428996

12 

L Badia V J Lund Vile bodies: an endoscopic approach to nasal myiasisJ Laryngol Otol199410812108312

13 

JA Villwock TM Harris Head and neck myiasis, cutaneous malignancy, and infection: a case series and review of the literatureJ Emerg Med2014472e3741

14 

TA Jan N Redjal BP Walcott Intranasal myiasis: a rare complication of transnasal skull base surgeryJ Clin Neurosci2013208117880

15 

R Beckendorf S A Klotz N Hinkle W Bartholomew Nasal myiasis in an intensive care unit linked to hospital-wide mouse infestationArch Intern Med2002162663840

16 

R Tai MA Marsh R Rao P Kurniali E DiNino E DiNino Nasal myiasis caused by cochliomyia hominivorax in the united states : A case reportAm J Infect Dis2011741079

17 

ZL White MW Chu RJ Hood Nasal Myiasis: A Case ReportEar Nose Throat J2015947245

18 

EN Ahadizadeh HR Ketchum R Wheeler Human cutaneous myiasis by the australian sheep blowfly, lucilia cuprina (diptera: calliphoridae), in oklahomaJ Forensic Sci20156041099100

19 

JS Kim PW Seo JW Kim JH Go SC Jang HJ Lee , A nasal myiasis in a 76-year-old female in KoreaKorean J Parasitol20094744057

20 

YT Lee TL Chen YC Lin CP Fung WL Cho Nosocomial nasal myiasis in an intubated patientJ Chin Med Assoc201174836971

21 

SC Gupta Permanent closure of the nostrils in recurrent nasal myiasisJ Laryngol Otol19789276278

22 

MAFB Baptista Nasal MyiasisN Engl J Med Overseas Ed201537212e1710.1056/NEJMicm1403473

23 

R Ranga SPS Yadav A Goyal A Agrawal Endoscopic Management of Nasal Myiasis: A 10 Years ExperienceClin Rhinol Int J201361586010.5005/jp-journals-10013-1152

24 

P Hoyer R R Williams M Lopez MM Cabada Human Nasal Myiasis Caused by Oestrus ovis in the Highlands of Cusco, Peru: Report of a Case and Review of the LiteratureCase Rep Infect Dis2016245673510.1155/2016/2456735

25 

K Schnizler B Saeger C Pfeffer A Gerbaulet U Ebbinghaus-Kintscher, C Methfessel A novel chloride channel in Drosophila melanogaster is inhibited by protonsJ Biol Chem2005280161625462

26 

A Crump Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectationsJ Antibiot20177049550510.1038/ja.2017.11

27 

AP Corrêa IM Beneti ED Ribeiro CCS Pereira FÁ Souza IR Garcia-Júnior Myiasis in elderly involving oral and nasal cavities-diagnosis and treatmentJ Craniofac Surg201526398990

28 

PJ Macdonald C Chan J Dickson F Jean-Louis A Heath Ophthalmomyiasis and nasal myiasis in New Zealand: a case seriesN Z Med J199911211004457

29 

F Babamahmoudi J Rafinejhad A Enayati Nasal myiasis due to lucilia sericata (meigen, 1826) from Iran: a case reportTrop Biomed20122911759

30 

DC Costa PT Pierre-Filho FM Medina Use of oral ivermectin in a patient with destructive rhino-orbital myiasisEye20051910182010.1038/sj.eye.6701713



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Article type

Case Report


Article page

12-15


Authors Details

Vartika Paliwal, Sudhakar Vaidya*


Article History

Received : 15-03-2024

Accepted : 11-04-2024


Article Metrics


View Article As

 


Downlaod Files